Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS
Business, Stock ReportsIf you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Psychedelic Stocks: ARK Invest and the Reverse Midas Touch
Business, Investing, Stock ReportsCathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance, is that a good thing?
Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses
Business, Stock ReportsThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline
Business, Stock ReportsMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
An Inside Look into Field Trip’s Next-Generation Psychedelic, FT-104
Business, ResearchField Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called FT-104. But how does it work?
Compass Pathways Sued for Stealing Trade Secrets
Business, ResearchCompass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
The Real Reason Cybin Bought Entheon’s DMT Clinical Trial
Business, Research, Stock ReportsIn a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
Project Solace: The World’s Largest Medical Psilocybin Access and Data Project
Business, ResearchProject Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian non-profit TheraPsil
3 Microdosing Clinical Trials to Keep an Eye On
Business, ResearchDoes microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Business, Stock ReportsCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research